Biopeople

Leading the way

Leading the way

24.10.2014 - Former Co-Head of Global Healthcare Investment Banking at J.P. Morgan, Andrea Ponti has taken over the role of non-executive director at Cell Medica, the London-based cellular therapeutics company.

With an extensive network of contacts and over 25 years of experience in advising leading pharmaceutical and biotechnology companies across the globe, Andrea Ponti will play an important role in developing partnership and commercialisation opportunities for Cell Media's immunotherapy products. Before joining J.P. Morgan in 2008, Ponti was Partner, Managing Director and Head of European Healthcare, Consumer and Retail investment banking at Goldman Sachs. In 1996, he founded the European Healthcare Group.

http://www.european-biotechnology-news.com/people/bio-people/2014/andrea-ponti.html

29.05.2014 Drug discovery provider Sygnature Discovery Ltd. has appointed Gerry Thomas as its new Director of Business Development.

Sygnature

Thomas spent more than 20 years in drug discovery and development at Boots Pharmaceuticals, BASF/Knoll, OSI Pharmaceuticals, Prosidion and Shire Pharmaceuticals. At Sygnature, the medicinal chemist will be instrumental in promoting the company’s integrated drug discovery capabilities and expertise across Europe and North America. 

27.05.2014 Drug giant Sanofi S.A. (Paris) has filled the newly-created position of Chief Patient Officer with Anne C. Beal, a public health specialist with a focus on providing access to high-quality health care.

Sanofi S.A.

Beal’s responsibility will be to infuse the patient perspective in Sanofi’s activities, ranging from early-stage R&D through to market availability of novel healthcare solutions. A pediatrician by profession, Beal joins Sanofi from the Patient Centered Outcomes Research Institute (PCORI), the United States’ largest research institute focused on patient-centered outcomes research, where she was Deputy Executive Director and Chief Officer for Engagement. Prior to PCORI, Beal was president of the Aetna Foundation, the independent charitable and philanthropic arm of Aetna Inc. She holds a B.A. from Brown University, an M.D. from Cornell University Medical College, and an M.P.H. from Columbia University. 

22.05.2014 F. Hoffmann-La Roche has promoted Genentech’s former VP of clinical hematology and oncology Dietmar Berger to lead the pharma giant’s clinical development for oncology and hematology.

Roche

He succeeds Sandra Homing, who was named Chief Medical Officer last January. Berger brings the company more than 20 years of experience in the field. Before joining Roche, he co-led oncology research at Bayer HealthCare AG and at Amgen Inc.

20.05.2014 Alessandra Cervino has joined Paris-based metagenomics specialist Enterome Bioscience SA as Head of Discovery.

Michael Guez

The 38-old reseacher brings the firm over 15 years of experience in the discovery and development of genetic and genomic biomarkers. Before joining Enterome, Cervino was VP R&D and Biostatistics at TCLand Expression, Head of Statistical Sciences at Scripps Florida, and group leader in statistical genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co.

15.05.2014 ADC specialist Glythera (UK) has named Ian Evetts as its new Commercial Director.

Glythera

Evett brings in more than 20 years experience in the pharmaceutical industry with a track record of senior strategic and operational roles, among them Managing Director at Atebion BDS Ltd., Strategic Advisor at Bionure and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies.

13.05.2014 Isarna Therapeutics GmbH (Munich) has named Elizabeth Czerepak to lead the company’s new office location in New York City as Chief Financial Officer and Chief Business Officer.

Isarna Therapeutics

Czerepak has a track record of 21 years in the biopharma industry and nine years as a venture capital investor at JP Morgan and Bear Stearns. She has served in various executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. Prior to CGI, Czerepak worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.

06.05.2014 The European Food Safety Authority’s Management Board has nominated Dr. Bernhard Url as EFSA’s next Executive Director.

EFSA

Following the departure of former Director Catherine Geslain-Lanéelle, Url has been EFSA’s acting Executive Director since the autumn of 2013. A qualified veterinarian by training, he brings high-level management experience from public and private food-safety organisations to the role, most recently as Managing Director for the Austrian Agency for Health and Food Safety (AGES). Until March 2012, Url served as a member of EFSA’s Management Board.

29.04.2014 Canbex Therapeutics Ltd has hired Alberto Lledó as its new Chief Medical Officer.

Canbex SL

Lledó will lead Canbex’s preparations in proof-of-concept trials for VSN16R, a small molecule for the treatment of spasticity in multiple sclerosis. Lledó is a Senior Consultant Neurologist at the Clínica Creu Blanca (Barcelona), and spent sixteen years at Eli Lilly. He will take over as Chief Medical Officer from Dr. Miroslav Ravic, who is guiding the company through the completion of its Phase I study. 

24.04.2014 Roche’s pRED unit has a new head of oncology and translational research.

Vanderbilt University Medical Center/Susan Urmy

William Pao, currently director at the Hematology-Oncology division and Personalised Cancer Medicine unit at Vanderbilt University Medical Center, will lead Roche’s discovery, translational medicine and early development of innovative oncology medicines. Pao, who has focused on academic clinical research in the past, is one of the world’s top oncology experts.

17.04.2014 Irish antibody developer Prothena Corporation plc has named Tara Nickerson as its Chief Business Officer.

Prothena Corp.

Previously she held the position of Head of Corporate and Business Development at the company, where she was instrumental during Prothena’s demerger from Elan and Prothena’s worldwide collaboration with Roche to develop and commercialise antibodies that target alpha-synuclein. Prior to Elan, Nickerson was a senior scientist at Celera Genomics (Axys Pharmaceuticals). 

Vorherige Seite4/21Nächste Seite

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 25.10.2014


Current issue

All issues

Product of the week

Products